21 citations
,
March 1982 in “JAMA” This study found that spironolactone at 200 mg/day effectively reduced facial hair growth in women with moderate to severe hirsutism, with improvements observed within two months and sustained over one year.
124 citations
,
September 1980 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that spironolactone significantly reduced hair growth in hirsute women, with noticeable effects in 3-5 months, and decreased serum testosterone levels in all participants.
60 citations
,
September 1979 in “Fertility and sterility” This study found that spironolactone reduced testosterone production and urinary 17-ketosteroid excretion, leading to a decrease in hair growth rate and a change in hair texture in women.
72 citations
,
June 1979 in “Biochemical Society Transactions” This research paper reviews the anti-androgenic properties of the drug flutamide and its metabolite Sch 16423 but presents no new experimental results.
129 citations
,
January 1977 in “Hormone and metabolic research” Cyproterone Acetate effectively treats androgen-related conditions and is used in prostate cancer therapy and hormone therapy for transgender women.
59 citations
,
January 1976 in “Vitamins and hormones” This chapter discusses androgen receptors and protein synthesis in the prostate, reporting that DHT-dependent receptor protein translocation increases protein-synthesizing activity after androgen injection in rat models.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” In this study, a treatment regimen combining cyproterone acetate and ethinyl estradiol significantly improved acne and seborrhoea in most women after three months, but had varied effects on hirsutism and alopecia.
87 citations
,
April 1973 in “Endocrinology” This study found that in hamster flank organs, 17βC inhibited enlargement caused by topical testosterone but not by DHT, suggesting potential use in androgen-related skin disorders like acne.
